 BEDFORD, Mass.--BUSINESS WIRE--Stoke Therapeutics, Inc. Nasdaq: STOK, a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced highlights from presentations being made at the American Epilepsy Society AES 2020 Virtual Annual Meeting December 4-8, 2020 related to the Companys work to advance STK-001, the first potential new medicine to target the underlying cause of Dravet syndrome. Dravet 